Elevated PSA with Prior Negative Biopsy: When to Repeat versus Observe

How to cite: Cooperberg MR. Elevated PSA with Prior Negative Biopsy: When to Repeat versus Observe. Grand Rounds in Urology. February 2026. Accessed Oct 2026. https://grandroundsinurology.com/elevated-psa-with-prior-negative-biopsy-when-to-repeat-versus-observe/

Summary

Matthew R. Cooperberg, MD, MPH, Professor of Epidemiology & Biostatistics, Department of Urology, Chief of the Urology Department, and Co-Leader of the Prostate Program, University of California, San Francisco, San Francisco, California, discusses the clinical dilemma of managing men with an elevated prostate-specific antigen (PSA) level after a prior negative prostate biopsy and outlines a modern approach that incorporates multiparametric magnetic resonance imaging (MRI), biomarkers, and individualized risk assessment.

A negative biopsy does not eliminate the possibility of clinically significant prostate cancer. Traditional systematic biopsy samples only a very small portion of the prostate gland, leaving the potential for missed tumors, particularly those located anteriorly or outside the standard sampling template. As a result, patients with persistently elevated PSA levels frequently face uncertainty about whether a repeat biopsy is necessary.

Dr. Cooperberg emphasizes that management decisions should move away from simple PSA thresholds and instead rely on a broader assessment of clinical risk. Patient age, PSA history, family history, prostate size, prior biopsy technique, and overall life expectancy should all be incorporated into the decision-making process. Shared decision-making with patients is essential.

Multiparametric MRI has become a central component of repeat evaluation. MRI can identify suspicious lesions that may have been missed on prior biopsy and enables targeted sampling of these regions. Even with targeted biopsy, systematic sampling is often performed simultaneously to detect multifocal disease.

Biomarker tests may further refine risk assessment in selected cases. Blood-, urine-, and tissue-based assays can help identify patients at higher risk of clinically significant prostate cancer, particularly grade group 2 or greater disease. These tools can also help reduce unnecessary repeat biopsies in men with lower-risk profiles.

Dr. Cooperberg emphasizes that the objective of repeat evaluation is not simply to detect cancer but to identify clinically meaningful cancers. The ultimate goal is to detect potentially lethal disease while minimizing unnecessary diagnosis and treatment of low-risk tumors.

The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 36 featured lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.

The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts.